within the quickly evolving discipline of oncology research, precise and economical mutation screening is very important for producing qualified therapies. The KRAS products and services Platform performs a pivotal part in this landscape by presenting extensive options for KRAS mutation profiling and Assessment. KRAS mutations, present in approxima